Survey shows providers have embraced telemedicine, but are experiencing higher rates of burnout.
In response to the COVID-19 pandemic, U.S. oncologists have adjusted patient care by embracing telemedicine and switching more patients to oral therapies to limit office visits—but personally, more oncologists may be experiencing burnout due to the loss of face-to-face interactions with patients, according to new research from Cardinal Health Specialty Solutions.
These findings were released today in the eighth edition of Oncology Insights, a research-based report series analyzing the views of more than 190 U.S. oncologists via surveys conducted in September through November 2020. This issue explores how oncologists are adapting their practices and caring for patients during the pandemic – and points to changes that may continue after COVID-19.
Nearly all participating oncologists (97%) said they used telemedicine during a peak stage of the pandemic, and they are generally satisfied with the experience. Nearly six in 10 participating oncologists said their telemedicine experience has been “highly positive” (10%) or “better than expected” (49%). About 80% of participating oncologists said they expect to continue using telemedicine with some patients after the pandemic.
For more information, click here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.